Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQN1 | ISIN: US76029N1063 | Ticker-Symbol: 7R8
Tradegate
20.12.24
18:15 Uhr
12,400 Euro
+0,400
+3,33 %
1-Jahres-Chart
REPLIMUNE GROUP INC Chart 1 Jahr
5-Tage-Chart
REPLIMUNE GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,90012,10022.12.
11,80012,10020.12.

Aktuelle News zur REPLIMUNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrReplimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.11.Replimune Prices Public Offering Of 6.923 Mln Common Shares At $13/Shr3
REPLIMUNE Aktie jetzt für 0€ handeln
26.11.Replimune prices $140M offering at $13 per share2
26.11.Replimune Group Inc: Replimune Announces Pricing of Upsized Public Offering2
25.11.Replimune looks to raise $125M through public offering2
25.11.Replimune announces $125 million public offering1
25.11.Replimune Group Inc: Replimune Announces Proposed Public Offering1
22.11.Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug14
22.11.US-Vorbörse: Gap, Ross Stores, Texas Pacific Land, Intuit und Replimune mit viel Bewegung19
22.11.Replimune's stock surges 19% after-hours on FDA BLA submission6
21.11.Replimune seeks FDA approval for melanoma treatment4
21.11.Replimune Group, Inc. - 8-K, Current Report-
21.11.Replimune beantragt FDA-Zulassung für Melanom-Behandlung8
21.11.Replimune Group Inc: Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway1
19.11.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
12.11.Replimune Group, Inc. - 10-Q, Quarterly Report-
12.11.Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts1
09.11.Replimune Group Inc: Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society ...67Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration...
► Artikel lesen
08.11.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)66WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...
► Artikel lesen
30.10.Replimune Group Inc: Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)1
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1